ライフサイエンスコーパス: angioplasty

1 a dedicated bifurcation stent or SB balloon angioplasty.

2 easing the risk of late thrombosis following angioplasty.

3 ncy among patients undergoing infrapopliteal angioplasty.

4 magnetic resonance (MR) imaging 3 days after angioplasty.

5 following percutaneous transluminal coronary angioplasty.

6 served in 5% of patients during test balloon angioplasty.

7 tery revascularization compared with balloon angioplasty.

8 ove vessel patency after superficial femoral angioplasty.

9 crophage invasion, and TLR4 expression after angioplasty.

10 ated balloon angioplasty or uncoated balloon angioplasty.

11 restenosis compared to conventional balloon angioplasty.

12 STEMI patients who are reperfused by primary angioplasty.

13 g to delayed vascular healing after stenting angioplasty.

14 g femoro-popliteal percutaneous transluminal angioplasty.

15 ecutive STEMI patients reperfused by primary angioplasty.

16 omes as compared with uncoated balloon (UCB) angioplasty.

17 evant web sites for trials of PCB versus UCB angioplasty.

18 itory MIS in the setting of planned coronary angioplasty.

19 y rats were given modified EPCs post-carotid angioplasty.

20 decrease neointimal hyperplasia post-carotid angioplasty.

21 trated in vivo in rat carotid arteries after angioplasty.

22 administrated into rats after carotid artery angioplasty.

23 m repeat interventions than standard balloon angioplasty.

24 limits the use of bypass surgery or balloon angioplasty.

25 repopulation of stented blood vessels after angioplasty.

26 ary artery bypass graft surgery, stents, and angioplasty.

27 ry branch occlusion during elective coronary angioplasty.

28 h a paclitaxel-coated balloon or to standard angioplasty.

29 fits of cardiovascular interventions such as angioplasty.

30 with the prevalence of percutaneous coronary angioplasty (-0.717; -0.787) and coronary artery bypass

31 acute aneurysm formation was 0% to 13% after angioplasty, 0% to 5% after bare metal stent placement,

32 d 104 were treated with conventional balloon angioplasty (18.5%).

33 rogressively declined from plain old balloon angioplasty (341% increase) to bare metal stent (218% in

34 rs consisted of 13 bypasses (4.3%), 18 patch angioplasties (6.0%), and 79 primary repairs (26.4%).

35 mong patients who had undergone conventional angioplasty (65.2% vs. 52.6%, P=0.02).

36 d balloon angioplasty is superior to balloon angioplasty alone for treatment of drug-eluting stent re

37 astomotic stenosis to undergo either balloon angioplasty alone or balloon angioplasty plus placement

38 taxel-coated balloon was superior to balloon angioplasty alone with a late loss of 0.43 +/- 0.61 mm v

39 er endovascular treatment for CoA, including angioplasty alone, bare metal stenting, and primary cove

40 consider for future clinical trials include angioplasty alone, indirect surgical bypass procedures,

41 nt restenosis compared with uncoated balloon angioplasty alone.

42 Percutaneous angioplasty along with metallic stent placement has been

43 elevation MI successfully treated by primary angioplasty and 16 matched controls were prospectively r

44 s, vessel remodeling during restenosis after angioplasty and atherosclerosis.

45 Studies from the balloon angioplasty and bare metal stent eras have demonstrated

46 sadvantages and limitations of plain balloon angioplasty and bare-metal stents, some limitations appl

47 tenosis following various interventions (eg, angioplasty and bypass grafting).

48 simultaneous right ventricular outflow tract angioplasty and CA angiography.

49 d by the prevalence of percutaneous coronary angioplasty and coronary artery bypass graft surgery.

50 Patients undergoing percutaneous coronary angioplasty and coronary artery bypass graft were identi

51 Coronary interventions, including balloon angioplasty and coronary stent implantation, are associa

52 e effectiveness research) shows that primary angioplasty and fibrinolysis have equivalent real-world

53 enic vascular injury associated with balloon angioplasty and stent deployment.

54 Angioplasty and stent implantation have become accepted

55 ena cava (IVC) and iliocaval confluence with angioplasty and stent implantation is very rare.

56 treat atherosclerosis, such as transluminal angioplasty and stent implantation, often cause vascular

57 Thirty-five patients underwent an angioplasty and stent implantation; 3 had cardiac surger

58 a cohort of 284 patients undergoing coronary angioplasty and stent placement (rs350099: TT versus CC+

59 on of iliofemoral stenosis or occlusion with angioplasty and stent placement has been increasingly us

60 Angioplasty and stent placement in right ventricle-to-pu

61 graphy and 20 patients treated with coronary angioplasty and stent placement.

62 gnificantly lower in patients treated by PEB angioplasty and stenting (34+/-31%) as compared with BA

63 and stenting (34+/-31%) as compared with BA angioplasty and stenting (56+/-29%, P=0.009) or DA (55+/

64 Restenosis after balloon angioplasty and stenting (BAS) remains an unsolved clini

65 with carotid endarterectomy (CEA) or carotid angioplasty and stenting (CAAS), the benefits from medic

66 efficacy, safety, and durability of carotid angioplasty and stenting (CAS) have been better defined

67 ain balloon angioplasty (BA) followed by PEB angioplasty and stenting (n=48), BA and stenting (n=52),

68 l group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0.0252).

69 being treated with percutaneous transluminal angioplasty and stenting (PTAS) to prevent recurrent str

70 tid revascularization with endarterectomy or angioplasty and stenting are established treatments for

71 Our results suggest that HAS angioplasty and stenting are minimally invasive and safe

72 Balloon angioplasty and stenting are the mainstays of endovascul

73 or target lesion revascularization after PEB angioplasty and stenting as compared with BA and stentin

74 ever, the newer technology of carotid artery angioplasty and stenting challenges this mode of interve

75 Balloon angioplasty and stenting form the backbone of endovascul

76 reover, endovascular drug delivery following angioplasty and stenting has been achieved with a marked

77 level 1 evidence comparing open bypass with angioplasty and stenting in TransAtlantic Inter-Society

78 RECENT FINDINGS: Percutaneous transluminal angioplasty and stenting is a treatment option for cereb

79 superficial femoral artery lesions with PEB angioplasty and stenting is superior to BA angioplasty a

80 Angioplasty and stenting is the primary treatment for fl

81 The Revascularization With Open Bypass vs Angioplasty and Stenting of the Lower Extremity Trial (R

82 B angioplasty and stenting is superior to BA angioplasty and stenting or DA in terms of angiographic

83 omized and receive percutaneous transluminal angioplasty and stenting or femoropopliteal bypass, resp

84 adverse outcomes in the ACT-1 trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asympt

85 Adjunctive angioplasty and stenting was performed in 19 (80%) patie

86 ndothelialization in a rat model of arterial angioplasty and stenting.

87 rtic valvuloplasty; coarctation of the aorta angioplasty and stenting; and pulmonary artery stenting.

88 opliteal bypass or percutaneous transluminal angioplasty and stenting; patients with TASC II A and D

89 Frequency of angioplasty and vascular stent implantation procedures i

90 f infrapopliteal interventions using balloon angioplasty and/or bare stents are limited by a relative

91 ents, -24.2% (-32.2 to -16.4) versus balloon angioplasty, and -31.8% (-44.8 to -18.6) versus rotablat

92 Study title, time period, indication for angioplasty, and outcomes were extracted manually from a

93 dies of the use of percutaneous transluminal angioplasty as primary treatment for patients with infra

94 osis after intervention using either balloon angioplasty (BA) alone or BA with stenting.

95 e randomized to treatment with plain balloon angioplasty (BA) followed by PEB angioplasty and stentin

96 t (ApoE(null)) mice without and with balloon angioplasty (BA) injury, a model of restenosis.

97 and efficacy of surgical, stent, and balloon angioplasty (BA) treatment of native coarctation acutely

98 An angioplasty balloon (1.5-2x6 mm) was used to deliver 1 t

99 ch in a complex boundary value problem where angioplasty balloon interacts with the vessel wall.

100 With A Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon), 300 symptomatic patients (Rutherfo

101 cokinetic Study of the Stellarex Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations w

102 blood serum of swine and patients undergoing angioplasty balloon-induced transient coronary occlusion

103 after full effacement of the stenosis by the angioplasty balloon.

104 Drug-coated angioplasty balloons deliver antiproliferative agents di

105 There remains a limited role for angioplasty because this intervention does not address t

106 k patients in registries have masked primary angioplasty benefit?

107 weeks after percutaneous transluminal, renal angioplasty blood pressure was normalized in all animals

108 duit tears are common in patients undergoing angioplasty, but clinically important tears, which only

109 rtery stenosis and were treated with balloon angioplasty by radiology.

110 Two balloon (percutaneous transluminal angioplasty) catheters were used.

111 cular event (myocardial infarction, coronary angioplasty, coronary artery bypass graft surgery, strok

112 Drug-coated balloon angioplasty (DCBA) was shown to be superior to standard

113 ficial femoral artery," "popliteal artery," "angioplasty," "drug-eluting balloon," "paclitaxel-elutin

114 n Peripheral Intervention for below the knee angioplasty evaluation (DEBATE-BTK) is a randomized, ope

115 Compared with balloon angioplasty, everolimus-eluting stent (hazard ratio [95%

116 rved predominantly for primary and secondary angioplasty failures.

117 was significantly lower in patients with PCB angioplasty for BMS restenosis compared with DES resteno

118 e prospectively enrolled patients undergoing angioplasty for dialysis access dysfunction.

119 ate referral or avoidance of cardiac surgery/angioplasty for high-risk patients, alteration of contra

120 On day 2 after successful primary angioplasty for STEMI, 53 patients were prospectively en

121 porary outcomes of percutaneous transluminal angioplasty for the treatment of infrapopliteal atherosc

122 on the effects of percutaneous transluminal angioplasty for the treatment of infrapopliteal lesions.

123 angioplasty was superior to uncoated balloon angioplasty for treatment of bare-metal stent (BMS) and

124 fine the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting stent restenos

125 allocation of higher-risk patients, primary angioplasty gave 22% lower mortality (odds ratio, 0.78;

126 in the stent-graft group than in the balloon-angioplasty group (32% vs. 16%, P=0.03 by the log-rank t

127 han in the percutaneous transluminal balloon angioplasty group (44.9%, P=0.002).

128 in the stent-graft group than in the balloon-angioplasty group (51% vs. 23%, P<0.001), as was the inc

129 nts in the percutaneous transluminal balloon angioplasty group and 77% in the nitinol stent group sho

130 nosis at 6 months was greater in the balloon-angioplasty group than in the stent-graft group (78% vs.

131 m in the cryoplasty and conventional balloon angioplasty groups, respectively (p=0.02).

132 vascular treatment, percutaneous endoluminal angioplasty has become particularly attractive for arter

133 We examined CCL activation at 14 primary angioplasty hospitals to determine the course of managem

134 PCB angioplasty in an all-comers, prospective, multicenter r

135 efficacy of paclitaxel-coated balloon (PCB) angioplasty in an international, multicenter, prospectiv

136 acement to percutaneous transluminal balloon angioplasty in patients with peripheral artery disease R

137 studied 450 patients 1-4 days after primary angioplasty in STEMI.

138 nction after percutaneous transluminal renal angioplasty in swine RAS.

139 d a major advancement over plain old balloon angioplasty in the management of coronary artery disease

140 ortant tears, which only occurred during UNC angioplasty in this series, were uncommon.

141 r homeostatic molecule that prevents balloon angioplasty-induced stenosis via antiproliferative effec

142 Common carotid artery (CCA) balloon angioplasty injury was performed in rats.

143 een achieved RF goals in the BARI 2D (Bypass Angioplasty Investigation Revascularization 2 Diabetes)

144 coronary angiography with simultaneous test angioplasty is an important step to evaluate for the pre

145 Drug-coated balloon angioplasty is associated with favorable results for tre

146 elective percutaneous transluminal coronary angioplasty is associated with myocardial ischemic damag

147 (GFR) after percutaneous transluminal renal angioplasty is difficult.

148 Peripheral percutaneous transluminal angioplasty is fraught with a substantial risk of resten

149 Angioplasty is increasingly more often used for correcti

150 Balloon angioplasty is inferior to all drug-eluting treatments f

151 rtery disease with percutaneous transluminal angioplasty is limited by the occurrence of vessel recoi

152 Balloon angioplasty is not different from cutting balloon (0.73

153 Paclitaxel-coated balloon angioplasty is superior to balloon angioplasty alone for

154 pment of thrombosis and abrupt closure after angioplasty is well recognized.

155 With the advent of thrombolytic therapy and angioplasty, it has become possible to reduce myocardial

156 ultrasound guidance during dialysis fistula angioplasty lead to cause more and more frequent employm

157 ities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claud

158 id revascularization and carotid stenting or angioplasty (low and insufficient SOE, respectively).

159 en and 239 men with STEMI undergoing primary angioplasty <12 hours after symptom onset.

160 myocardial infarction reperfused by primary angioplasty (<12 hours after symptom onset) in this card

161 Intentional fracture with UHP balloon angioplasty may be considered when treating stents that

162 Below the knee, angiosome-directed angioplasty may lead to greater wound healing, but faili

163 In a rat venous patch angioplasty model, control patches developed robust neoi

164 response to injury in a rat carotid balloon angioplasty model.

165 stenosis in a porcine femoral artery balloon angioplasty model.

166 stenosis in a porcine femoral artery balloon angioplasty model.

167 nded end-to-end anastomosis (n = 632), patch angioplasty (n = 72), interposition grafting (n = 49), b

168 bolysis In Myocardial Infarction flow before angioplasty (odds ratio, 0.50; 95% confidence interval,

169 alloon aortic valvuloplasty, and stenting or angioplasty of Blalock-Taussig shunts.

170 Acute hemodynamic changes after angioplasty of homografts with UNC balloons included sig

171 The 1-year restenosis rate after balloon angioplasty of long lesions in below-the-knee arteries m

172 Safety and efficacy of angioplasty of obstructed RV-PA homografts using ultra-n

173 The TLR rate did not differ for PCB angioplasty of paclitaxel-eluting stent and non-paclitax

174 analyzed in 109 patients undergoing elective angioplasty of right or circumflex coronary arteries.

175 012, 70 patients underwent 76 procedures for angioplasty of RV-PA homografts with UNC Atlas balloons.

176 of the main branch with our without balloon angioplasty of the side branch offers hemodynamic advant

177 The patient underwent balloon angioplasty of the stenotic SVC segment with resolution

178 giography; 119/137 (86.9%) were treated with angioplasty, of which 113/137 (82.5%) were stented.

179 Primary angioplasty offers a less invasive option for specific a

180 Since the first coronary angioplasty on Sept 16, 1977, the field of percutaneous

181 creased all-cause mortality included balloon angioplasty or bare-metal stent placement compared with

182 n allocation of high-risk patient to primary angioplasty or fibrinolysis and mortality.

183 ver, prior trials compared CABG with balloon angioplasty or older generation stents, and it is not kn

184 r, and measures protective against AWI after angioplasty or stent implantation for CoA.

185 onary artery (CA) compression during balloon angioplasty or stent placement in the overlying conduit.

186 and LDL cholesterol values, and intracranial angioplasty or stent placement, or both, in selected pat

187 branch stenting without side branch balloon angioplasty or stenting provided the most favorable hemo

188 long-term results for freedom from coronary angioplasty or stenting, renal dysfunction, diabetes mel

189 75 mg daily, before and after infrainguinal angioplasty or stenting.

190 coronary artery to paclitaxel-coated balloon angioplasty or uncoated balloon angioplasty.

191 ntervention (PCI) either by means of balloon angioplasty or with the use of bare-metal stents, result

192 arterial disease, carotid endarterectomy or angioplasty, or abdominal aortic aneurysm repair).

193 grafting, percutaneous transluminal coronary angioplasty, or angiographic evidence of significant ste

194 e presence of angina, myocardial infarction, angioplasty, or bypass surgery in a relative <50 years o

195 dial infarction (MI), coronary intervention (angioplasty, or coronary artery bypass surgery), angina

196 The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patient

197 a post hoc analysis of the Second Medicine, Angioplasty, or Surgery Study (MASS II), which is a rand

198 observed for most percutaneous transluminal angioplasty outcomes.

199 vivo vascular retention during percutaneous angioplasty over nontargeted controls.

200 graft and percutaneous transluminal coronary angioplasty (p<0.001 and p=0.005, respectively).

201 drug-coated balloon and 79.0% with standard angioplasty (P=0.005 for noninferiority).

202 ytherapy, and 18.0% for conventional balloon angioplasty (P=0.57).

203 tients who underwent surgery (CABG) or stent angioplasty (PCI).

204 (CABG), 'percutaneous transluminal coronary angioplasty' (PCTA) and 'Other Coronary Heart Disease'.

205 randomly assigned to DCB (n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]

206 either balloon angioplasty alone or balloon angioplasty plus placement of the stent graft.

207 was shown to be superior to standard balloon angioplasty (POBA) in terms of restenosis prevention for

208 ary intervention (PCI) (43 plain old balloon angioplasty [POBA] and 41 DES) were analyzed to assess t

209 oronary artery bypass graft surgery/coronary angioplasty procedure/stent (1.35; 1.08-1.69), or any of

210 ess commonly in the others, with coarctation angioplasty procedures being the least successful (51%).

211 ntrol cohort of 81 patients who underwent 84 angioplasty procedures with conventional balloons.

212 based clinics exceeded those of stenting and angioplasty procedures.

213 imb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out bare metal stenting (BMS)

214 ntion rates versus percutaneous transluminal angioplasty (PTA) and improve wound healing/limb preserv

215 pared the DES with percutaneous transluminal angioplasty (PTA) and provisional bare-metal stent (BMS)

216 DCB or an uncoated percutaneous transluminal angioplasty (PTA) balloon.

217 underwent balloon percutaneous transluminal angioplasty (PTA) between January 2009 and December 2012

218 ersus conventional percutaneous transluminal angioplasty (PTA) for the reduction of restenosis in dia

219 oated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic super

220 01) than those for percutaneous transluminal angioplasty (PTA), as were radiation exposures to the ha

221 with conventional percutaneous transluminal angioplasty (PTA), yet durability of the treatment effec

222 tenting or percutaneous transluminal balloon angioplasty (PTA).

223 rate of SFA after percutaneous transluminal angioplasty (PTA).

224 ndard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100).

225 ization with percutaneous transluminal renal angioplasty (PTRA) and stenting often fails to recover r

226 ransfer decreased neointimal formation in an angioplasty rat model by preventing vascular smooth musc

227 ed from the Swedish Coronary Angiography and Angioplasty Register between 2009 and 2013 and linked wi

228 mprehensive Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and end points evaluated th

229 included in the Swedish Coronary Angiography Angioplasty Registry (SCAAR) between 2006 and 2010 and w

230 part of the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

231 l using the Swedish Coronary Angiography and Angioplasty Registry for enrollment.

232 wide SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

233 the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

234 the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

235 ted patients with MIS both in the setting of angioplasty-related MIS (area under the curve 0.94) and

236 The torn wall was treated by patch angioplasty, resulting in a permanent IVC occlusion, as

237 disease burden was determined by the Bypass Angioplasty Revascularization Investigation (BARI) myoca

238 us and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (

239 The Bypass Angioplasty Revascularization Investigation 2 Diabetes (

240 The Bypass Angioplasty Revascularization Investigation 2 Diabetes (

241 ects were compared in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (

242 ents (702 white, 175 blacks) from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (

243 Bypass Angioplasty Revascularization Investigation 2 Diabetes (

244 (Bypass Angioplasty Revascularization Investigation 2 Diabetes [

245 essive Drug Evaluation; NCT00007657) (Bypass Angioplasty Revascularization Investigation 2 Diabetes [

246 omen and men enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

247 oup, (n = 766 of 2,287), the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

248 cumented CAD enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

249 with medical therapy in the BARI-2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

250 (Bypass Angioplasty Revascularization Investigation in Type 2 Di

251 (Bypass Angioplasty Revascularization Investigation in Type 2 Di

252 In the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Di

253 (Bypass Angioplasty Revascularization Investigation in Type 2 Di

254 eart disease and were enrolled in the Bypass Angioplasty Revascularization Investigation in Type 2 Di

255 diseases, particularly restenosis following angioplasty, stent implantation, or vein grafting.

256 bypass and 5 with percutaneous transluminal angioplasty stenting of the subclavian).

257 y successful percutaneous transluminal renal angioplasty+stenting.

258 Paclitaxel-eluting balloon (PEB) angioplasty, stenting, and directional atherectomy (DA)

259 Percutaneous transluminal renal angioplasty/stenting (PTRAS) is frequently used to treat

260 Portal vein angioplasty/stenting is conventionally performed through

261 part of a percutaneous transluminal balloon angioplasty strategy has equivalent 1-year patency and s

262 controlled trials consistently find primary angioplasty superior.

263 been due to the iteration and improvement of angioplasty technologies.

264 ation laboratory for guide wire crossing and angioplasty the next day.

265 Balloon angioplasty, the first-line therapy, has a tendency to l

266 n anterior STEMI patients undergoing primary angioplasty, the sooner IV metoprolol is administered in

267 least one invasive intervention (22 patients angioplasty/thrombolysis, 62 TIPS, and 20 OLT) and 36 (2

268 a step-wise approach using anticoagulation, angioplasty/thrombolysis, transjugular intrahepatic port

269 carotid arteries were injured using balloon angioplasty to cause neointimal hyperplasia.

270 e describe the technique of dialysis fistula angioplasty under ultrasound control.

271 r femoro-popliteal percutaneous transluminal angioplasty up to 1 year of follow-up.

272 gene transfer to arteries treated with stent angioplasty using a 2-source magnetic guidance strategy.

273 e or inhibit, respectively, restenosis after angioplasty, vein graft intimal thickening and atherogen

274 series, PA stent fracture using UHP balloon angioplasty was feasible and did not result in major com

275 In drug-eluting stent ISR, balloon angioplasty was inferior to everolimus-eluting stent (0.

276 Balloon angioplasty was limited by unpredictable procedural outc

277 PCB angioplasty was more effective in BMS restenosis compare

278 PCB angioplasty was performed in 1,523 patients (72.7%) with

279 In small randomized trials, PCB angioplasty was superior to uncoated balloon angioplasty

280 al, 738 STEMI patients reperfused by primary angioplasty were enrolled in 8 centers.

281 disease undergoing percutaneous transluminal angioplasty were randomized to paclitaxel-coated IN.PACT

282 olar catheter or an alligator-clip-connected angioplasty wire.

283 of IH in various animal models (e.g. balloon angioplasty, wire injury, and vein graft), but very few

284 , bypass surgical procedures, and peripheral angioplasties with and without a stent.

285 cally significant atherosclerotic lesions to angioplasty with a paclitaxel-coated balloon or to stand

286 al artery disease, percutaneous transluminal angioplasty with a paclitaxel-coated balloon resulted in

287 12 months that was higher than the rate with angioplasty with a standard balloon.

288 was designed to compare conventional balloon angioplasty with an expanded polytetrafluoroethylene end

289 rate was low and did not differ between PCB angioplasty with and without additional BMS implantation

290 A rabbit model of arterial angioplasty with local delivery of RvD2 (10 nM vs. vehic

291 antirestenotic efficacy as compared with UCB angioplasty with no evidence of a differential safety pr

292 The rate of peripheral angioplasty with or without a stent was higher among the

293 Angioplasty with PCB versus UCB reduces target lesion re

294 reased surgical risk, SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for

295 r-level factors, as well as the Stenting and Angioplasty With Protection in Patients at High Risk for

296 and harms of percutaneous transluminal renal angioplasty with stent placement (PTRAS) versus medical

297 compression resulting in symptoms, although angioplasty with stenting may be used in recalcitrant ca

298 is performed as single or multiple coronary angioplasty with stenting using either bare metal or dru

299 ary patency among patients who had undergone angioplasty with the drug-coated balloon was superior to

300 ficant reductions in pressure gradient after angioplasty, with no difference in postangioplasty gradi